Aurora Bio, Inc.

South San Francisco, CA · Biotech · Private

Synthetic polybasic peptides and antibody-peptide fusion constructs that bind amyloid fibrils for imaging and therapeutic targeting of cardiac amyloidosis

aurorabioinc.com →
Grants
$500K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Immunotherapeutic for ATTR/AL Cardiac Amyloidosis$249,752
Federal grantDepartment of Health and Human Services · Phase I · Immunotherapeutic for ATTR/AL Cardiac Amyloidosis$249,752
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2597Nascent Biotech Inc.—$543K
2598Mitochondria in Motion, Inc.——
2599SKYRAN BIOLOGICS, INC.——
2600Aurora Bio, Inc.——
2601NEURODON, LLC—$500K
2602JumpStart Fertility, Inc.—$500K
2603ENFUEGO THERAPEUTICS, INC.—$500K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.